Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.45 Million EUR | 45.5% |
| 2022 | -10.05 Million EUR | 19.16% |
| 2021 | -12.44 Million EUR | 11.97% |
| 2020 | -14.13 Million EUR | 3.36% |
| 2019 | -14.62 Million EUR | -159.84% |
| 2018 | -5.62 Million EUR | -3.4% |
| 2017 | -5.44 Million EUR | -71.85% |
| 2016 | -3.16 Million EUR | 8.04% |
| 2015 | -3.44 Million EUR | -38.05% |
| 2014 | -2.49 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.33 Million EUR | 0.0% |
| 2024 Q1 | -2.33 Million EUR | -33.23% |
| 2023 Q1 | -1.47 Million EUR | 75.22% |
| 2023 Q2 | -3.08 Million EUR | -109.43% |
| 2023 Q3 | -1.85 Million EUR | 39.82% |
| 2023 FY | -5.48 Million EUR | 45.5% |
| 2023 Q4 | -1.75 Million EUR | 5.52% |
| 2022 Q3 | -2.84 Million EUR | 40.41% |
| 2022 Q1 | -2.21 Million EUR | 60.57% |
| 2022 FY | -10.05 Million EUR | 19.16% |
| 2022 Q4 | -5.95 Million EUR | -109.14% |
| 2022 Q2 | -4.77 Million EUR | -115.87% |
| 2021 FY | -12.44 Million EUR | 11.97% |
| 2021 Q4 | -5.61 Million EUR | -128.75% |
| 2021 Q3 | -2.45 Million EUR | 69.07% |
| 2021 Q2 | -7.92 Million EUR | -109.85% |
| 2021 Q1 | -3.77 Million EUR | 41.81% |
| 2020 Q4 | -6.49 Million EUR | -99.97% |
| 2020 Q1 | -3.85 Million EUR | 48.79% |
| 2020 Q3 | -3.24 Million EUR | 57.91% |
| 2020 Q2 | -7.71 Million EUR | -100.0% |
| 2020 FY | -14.13 Million EUR | 3.36% |
| 2019 Q3 | -3.73 Million EUR | 44.95% |
| 2019 Q1 | -3.38 Million EUR | -295.82% |
| 2019 FY | -14.62 Million EUR | -159.84% |
| 2019 Q4 | -7.53 Million EUR | -101.61% |
| 2019 Q2 | -6.78 Million EUR | -100.3% |
| 2018 Q4 | -855.93 Thousand EUR | 0.0% |
| 2018 Q3 | -855.93 Thousand EUR | 56.91% |
| 2018 Q1 | -1.98 Million EUR | -7.41% |
| 2018 Q2 | -1.98 Million EUR | 0.0% |
| 2018 FY | -5.62 Million EUR | -3.4% |
| 2017 Q4 | -1.84 Million EUR | 0.0% |
| 2017 Q2 | -1.13 Million EUR | 0.0% |
| 2017 Q1 | -1.13 Million EUR | -42.19% |
| 2017 FY | -5.44 Million EUR | -71.85% |
| 2017 Q3 | -1.84 Million EUR | -62.59% |
| 2016 FY | -3.16 Million EUR | 8.04% |
| 2016 Q1 | -784 Thousand EUR | 0.0% |
| 2016 Q2 | -784 Thousand EUR | 0.0% |
| 2016 Q3 | -800 Thousand EUR | -2.04% |
| 2016 Q4 | -800 Thousand EUR | 0.0% |
| 2015 FY | -3.44 Million EUR | -38.05% |
| 2014 FY | -2.49 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -89.244% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 94.931% |
| Adocia SA | -17.62 Million EUR | 63.358% |
| Aelis Farma SA | -6.46 Million EUR | 0.062% |
| Biophytis S.A. | -14.33 Million EUR | 54.95% |
| genOway Société anonyme | 2.06 Million EUR | 412.643% |
| IntegraGen SA | -183.77 Thousand EUR | -3413.631% |
| Medesis Pharma S.A. | -4.22 Million EUR | -52.672% |
| Neovacs S.A. | -6.9 Million EUR | 6.523% |
| NFL Biosciences SA | -4.43 Million EUR | -45.742% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -729.696% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -105.817% |
| Sensorion SA | -22.31 Million EUR | 71.059% |
| Theranexus Société Anonyme | -7.64 Million EUR | 15.525% |
| TME Pharma N.V. | -5.62 Million EUR | -14.812% |
| Valbiotis SA | -7.16 Million EUR | 9.818% |
| TheraVet SA | -2.17 Million EUR | -196.859% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 68.173% |
| argenx SE | -417.15 Million EUR | 98.452% |
| BioSenic S.A. | -7.04 Million EUR | 8.281% |
| Celyad Oncology SA | -8.45 Million EUR | 23.649% |
| DBV Technologies S.A. | -85.24 Million EUR | 92.425% |
| Galapagos NV | -88.26 Million EUR | 92.684% |
| Genfit S.A. | -26.58 Million EUR | 75.707% |
| GeNeuro SA | -14.35 Million EUR | 55.026% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 59.626% |
| Innate Pharma S.A. | -12.66 Million EUR | 49.033% |
| Inventiva S.A. | -102.7 Million EUR | 93.713% |
| MaaT Pharma SA | -19.94 Million EUR | 67.623% |
| MedinCell S.A. | -20.97 Million EUR | 69.219% |
| Nanobiotix S.A. | -26.77 Million EUR | 75.888% |
| Onward Medical N.V. | -35.46 Million EUR | 81.792% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -41.937% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 71.909% |
| Oxurion NV | -12.11 Million EUR | 46.68% |
| Pharming Group N.V. | -4.87 Million EUR | -32.328% |
| Poxel S.A. | -28.76 Million EUR | 77.552% |
| GenSight Biologics S.A. | -29.69 Million EUR | 78.256% |
| Transgene SA | -30.01 Million EUR | 78.485% |
| Financière de Tubize SA | -2.14 Million EUR | -201.17% |
| UCB SA | 604 Million EUR | 101.069% |
| Valneva SE | -82.08 Million EUR | 92.134% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 77.609% |